Moreover, back pain in patients who did not sustain a fracture during the follow-up period would reduce due to the natural course of the disease [2]. EFOS provided information on the use of different osteoporosis medications after the end of teriparatide treatment in normal clinical practice. The majority of patients Selleckchem MGCD0103 (70.7%) received

antiresorptives (primarily bisphosphonates). Whether it was the long-term pharmacological effect of teriparatide on bone tissue, the contribution of this sequential medication, or both that affected the post-treatment risk of fracture is unclear, but the clinically relevant finding was that there was no evidence of deterioration in the odds of fracture or a rebound increase

in back pain after teriparatide was discontinued. Antiresorptives such as alendronate, calcitonin and raloxifene have been reported to reduce back pain in postmenopausal women with osteoporosis [29–35]. It is unclear why we did not observe a further decline in back pain after teriparatide discontinuation when most patients were receiving antiresorptives. One P005091 mw possible explanation is that the patients had already reached a low level of back pain (~30 mm). Our study has several limitations. First, the results are specific to postmenopausal Batimastat women with severe osteoporosis and may not be applicable to other types of patients receiving teriparatide. Second, we did not determine morphometric Astemizole vertebral fractures as X-rays were only performed in symptomatic patients, so we may have underestimated the effectiveness in overall risk of vertebral fracture. Third, we did not gather data on the use of analgesics during the study. Fourth, the study was not designed to examine the maintenance of fracture efficacy after discontinuation of treatment, and the wide CIs show lack of power to determine

fracture efficacy after teriparatide treatment was discontinued. Finally, the lack of a randomised control group prevents determination of the cause of the observed findings, especially subjective symptoms, such as back pain. The strengths of the EFOS study include the prospective examination of clinical fractures in postmenopausal women with osteoporosis in real-life clinical practice both during teriparatide therapy and after teriparatide discontinuation. We also evaluated changes in pain over time using patient-completed instruments, thereby gaining the patients’ perspective. Our analyses adjusted for factors that may influence back pain, such as age, baseline level of pain, co-morbid rheumatoid arthritis, prior medication and fracture history.